Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular Neurons

Simon Akerman, Philip R. Holland, and Peter J. Goadsby
Headache Group, Institute of Neurology and the National Hospital for Neurology and Neurosurgery, Queen Square, London,
United Kingdom
Received April 29, 2006; accepted October 2, 2006

ABSTRACT
Migraine is a common and disabling neurological disorder that involves activation or the perception of activation of the trigeminovascular system. Cannabinoid (CB) receptors are present in brain and have been suggested to be antinociceptive. Here we determined the effect of cannabinoid receptor activation on … [CONTINUE READING / FULL PDF]

       

About The Author

iPharmaTrials.com

Twitter @iPharmaTrials // International Pharma Trials

Resources

 

iPT Tweets

 

iPHARMA TRIALS

 

New York, USA
Telephone : 718-332-7878
rkrishna -AT- ipharmatrials.com
.. replace -AT- with @

United Kingdom
The Studio/East Batterlaw Farm
Seaham SR7 8RP

Corporation Registration Address:
330 Thornton Road Englewood NJ 07631